Skip to main content
  • Saved

Commented on 's Post

Cardiovascular disease risks in younger versus older adult B-cell non-Hodgkin's lymphoma survivors - PubMed

Cardiovascular disease risks in younger versus older adult B-cell non-Hodgkin's lymphoma survivors - PubMed

Source :

https://pubmed.ncbi.nlm.nih.gov/33979029/

doi: 10.1002/cam4.3934. Online ahead of print. 1 Division of Public Health, Department of Family & Preventive Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA. 2 Huntsman Cancer Institute, Salt Lake City, UT, USA. 3 Intermountain Healthcare, Salt Lake City, UT, USA.

  • 1 month

    Key Points
    • In the current epidemiology study, researchers mined the Utah Cancer Registry to assess cardiovascular disease (CVD) risk among younger versus older B-cell non-Hodgkin's lymphoma (B-NHL) survivors. They also compared both these cohorts with the general population.
    • They found that compared with older survivors, younger B-NHL survivors exhibited higher relative risks for chronic rheumatic disease of the heart valves; pericarditis, endocarditis, and myocarditis; arterial disease; and hypotension. Of note, survivors from both groups exhibited higher risks of overall heart disease and congestive heart failure.
    • Limitations of the current study included the potential for participants to be diagnosed with cardiovascular outcomes that weren’t documented in the databases utilized. Additionally, some participants lacked BMI data and, because ICD codes were used to identify smoking status, only heavy smokers with complications were assessed. Another limitation was that the broad categories used to gather treatment data failed to address type of drug, dosage, specific chemotherapy cycles, and duration of treatment.
    • “In conclusion,” the authors wrote, “we observed elevated relative risks of specific long‐term CVD outcomes in younger B‐NHL survivors compared with their older counterparts. Potential reasons for the increased risks include treatment‐associated side effects and presence of preexisting comorbidities, suggesting a need for monitoring and management of these outcomes in young B‐NHL survivors. Although these increased disease risks suggest some early aging for younger B‐NHL survivors, most CVD relative risks were not different between the two age groups. Future studies specifically observing these CVD outcomes prospectively are warranted.”